Back

Europe surveillance initiative profiling the activity of telavancin against streptococci by specimen source from 2004 to 2005

Abstract number: 1733_321

Draghi D., Benton B., Jones M., Krause K., Thornsberry C., Sahm D.

Objectives: Telavancin (TLV) is a novel, rapidly bactericidal lipoglycopeptide with potent activity against a wide spectrum of Gram-positive bacteria. TLV has recently completed two Phase 3 clinical trials for the treatment of complicated skin and skin structure infections. Ongoing trials are assessing TLV for the treatment of hospital-acquired pneumonia. The current study was performed to establish a baseline of TLV activity versus recent isolates of various streptococcal species that may be encountered in the clinical setting.

Methods: During 2004–2005, 168 Streptococcus pneumoniae (SP), 67 viridans streptococci (VGS) and 106 b-haemolytic streptococci (BS; including 46 S. pyogenes, 42 S. agalactiae and 18 Group C, G and F streptococci) were collected from Europe (33 hospital sites in 14 countries). Isolates were centrally tested by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) methodology (M7-A7) against TLV and comparators. Isolates were analysed in groups by specimen source (SPEC), which included blood, lower respiratory tract, upper respiratory tract and skin structure.

Results: The table shows the activity of TLV against the different streptococcal isolates.

Activity of telavancin against Streptococcus pneumoniae (SP), viridans streptococci (VGS) and b-haemolytic streptococci (BS) isolates

OrganismSpecimen sourceaPhenotypebNo. of isolatesMIC (mg/L)
RangeMIC90  
SPBloodAll52<=0.001–0.060.03
PEN-S44<=0.001–0.060.03   
PEN-NS80.015–0.03NAc  
LRTAll670.002–0.030.03  
PEN-S420.002–0.030.03   
PEN-NS250.015–0.030.03   
URTAll490.008–0.030.03  
PEN-S350.008–0.030.03   
PEN-NS140.015–0.030.03   
VGSBloodAll400.03–0.50.12
ERY-S210.03–0.50.12   
ERY-NS190.03–0.120.12   
SSTAll270.015–0.50.06  
ERY-S170.03–0.06–0.06    
ERY-NS100.015–0.50.06   
BSBloodAll26<=0.001–0.250.06
ERY-S210.015–0.250.06   
ERY-NS5<=0.001–0.06Nac   
SSTAll800.002–0.120.06  
ERY-S590.002–0.120.06   
ERY-NS210.015–0.120.06   
aLRT, lower respiratory tract; URT, upper respiratory tract; SST, skin structure.bPEN-S/PEN-NS, penicillin-susceptible/nonsusceptible; ERY-S/ERY-NS, erythromycin-susceptible/nonsusceptible.cNA, not available; MIC90 values were not determined for <10 isolates.

Conclusion: TLV demonstrated potent activity against all streptococcal species and groups encountered in this surveillance initiative, regardless of resistance to other antimicrobial classes. TLV MIC90 values for each streptococcal group were equivalent or within one doubling dilution when studied by SPEC. This baseline evaluation provides a useful benchmark of TLV activity as clinical development and use progresses.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top